As of Thursday close, Aclaris Therapeutics Inc.’s (NASDAQ:ACRS) stock was up $0.05, moving up 0.74 percent to $6.82. The average number of shares traded per day over the past five days has been 1,087,160 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.18 fall in that time frame. In the last twenty days, the average volume was 1,047,450, while in the previous 50 days, it was 731,458.
Since last month, ACRS stock retreated -9.55%. Shares of the company fell to $6.49 on 09/21/23, the lowest level in the past month. A 52-week high of $18.96 was reached on 01/30/23 after having rallying from a 52-week low of $5.77. Since the beginning of this year, ACRS’s stock price has dropped by -56.70% or -$8.93, and marked a new high 8 times. However, the stock has declined by -64.03% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ACRS stock investors should be aware that Aclaris Therapeutics Inc. (ACRS) stock had its last reported insider trading activity 16 days ago on Sep 06. Balthaser Kevin, the Chief Financial Officer of the company, purchased of 9,490 shares for $7.90 on Sep 06. It resulted in a $74,971 investment by the insider. Loerop James added 14,705 shares at an average price of $6.80 on Aug 28. The insider now owns 21,688 shares following the transaction. On Aug 21, Chief Scientific Officer Monahan Joseph sold 6,000 shares at $7.32 apiece. The transaction was valued at $43,895.
Valuation Metrics
The stock’s beta is 0.68. Besides these, the trailing price-to-sales (P/S) ratio of 16.40, the price-to-book (PB) ratio of 2.69.
Financial Health
In the three months ended June 29, Aclaris Therapeutics Inc.’s quick ratio stood at 5.80, while its current ratio was 5.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 57.70% percent. Based on annual data, ACRS earned $17.79 million in gross profit and brought in $29.75 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -45.50%. Return on equity (ROE) for the past 12 months was -54.40%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ACRS’s revenue rose 18.18% to $2.53 million during the quarter, while net income inched up to $1.87 million. While analysts expected Aclaris Therapeutics Inc. to report -$0.45 quarterly earnings, the actual figure was -$0.42 per share, beating the consensus estimate by 6.70%. During the quarter, the company generated -$31.6 million in EBITDA. The liabilities of Aclaris Therapeutics Inc. were 55.9 million at the end of its most recent quarter ended June 29, and its total debt was $2.36 million. The value of shareholders’ equity is $70.8 million.
Technical Picture
This quick technical analysis looks at Aclaris Therapeutics Inc.’s (ACRS) price momentum. With a historical volatility rate of 59.37%, the RSI 9-day stood at 32.27% on 21 September.
With respect to its five-day moving average, the current Aclaris Therapeutics Inc. price is down by -14.75% percent or -$1.18. At present, ACRS shares trade -6.19% below its 20-day simple moving average and -23.28% percent below its 100-day simple moving average. However, the stock is currently trading approximately -36.73% below its SMA50 and -59.01% below its SMA200.
Stochastic coefficient K was 15.45% and Stochastic coefficient D was 27.10%, while ATR was 0.49. Given the Stochastic reading of 18.49% for the 14-day period, the RSI (14) reading has been calculated as 35.21%. As of today, the MACD Oscillator reading stands at -0.45, while the 14-day reading stands at -0.56.
Analyst Ratings
Stifel launched its rating on Aclaris Therapeutics Inc. (NASDAQ: ACRS) to a Buy in a note to investors on December 14, 2022. Aclaris Therapeutics Inc. (ACRS) has been rated Buy by analysts. According to 0 brokerage firms, ACRS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Aclaris Therapeutics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $29.50, the current consensus forecast for the stock is $20.00 – $43.00. Based on these forecasts, analysts predict Aclaris Therapeutics Inc. (ACRS) will achieve an average price target of $30.63.
